Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK

R&eacute;mi Marty1, St&eacute;phane Roze1, Hannah Kurth21HEVA, Lyon, 2IPSEN, Boulogne-Billancourt, FranceBackground: Long-acting somatostatin receptor ligands (SRL) with product-specific formulation and means of administration are injected periodically in patients with acromegaly and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marty R, Roze S, Kurth H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/bf41481cd3594a0682ad4b04ce87116f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bf41481cd3594a0682ad4b04ce87116f
record_format	dspace
spelling	oai:doaj.org-article:bf41481cd3594a0682ad4b04ce87116f2021-12-02T04:07:00ZDecision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK1179-1470https://doaj.org/article/bf41481cd3594a0682ad4b04ce87116f2012-05-01T00:00:00Zhttp://www.dovepress.com/decision-tree-model-for-health-economic-comparison-of-two-long-acting--a9789https://doaj.org/toc/1179-1470R&eacute;mi Marty1, St&eacute;phane Roze1, Hannah Kurth21HEVA, Lyon, 2IPSEN, Boulogne-Billancourt, FranceBackground: Long-acting somatostatin receptor ligands (SRL) with product-specific formulation and means of administration are injected periodically in patients with acromegaly and neuroendocrine tumors. A simple decision-tree model aimed at comparing cost savings with ready-to-use Somatuline Autogel&reg; (lanreotide) and Sandostatin LAR&reg; (octreotide) for the UK, France, and Germany. The drivers of cost savings studied were the reduction of time to administer as well as a reduced baseline risk of clogging during product administration reported for Somatuline Autogel&reg;.Methods: The decision-tree model assumed two settings for SRL administration, ie, by either hospital-based or community-based nurses. In the case of clogging, the first dose was assumed to be lost and a second injection performed. Successful injection depended on the probability of clogging. Direct medical costs were included. A set of scenarios were run, varying the cost drivers, such as the baseline risk of clogging, SRL administration time, and percentage of patients injected during a hospital stay.Results: Costs per successful injection were less for Somatuline Autogel&reg;/Depot, ranging from Euros (EUR) 13-45, EUR 52-108, and EUR 127-151, respectively, for France, Germany, and the UK. The prices for both long-acting SRL were the same in France, and cost savings came to 100% from differences other than drug prices. For Germany and the UK, the proportion of savings due to less clogging and shorter administration time was estimated to be around 32% and 20%, respectively. Based on low and high country-specific patient cohort size estimations of individuals eligible for SRL treatment among the patient population with acromegaly and neuroendocrine tumors, annual savings were estimated to be up to EUR 2,000,000 for France, EUR 6,000,000 for Germany, and EUR 7,000,000 for the UK.Conclusion: This model suggests that increasing usage of the Somatuline device for injection of SRL might lead to substantial savings for health care providers across Europe.Keywords: clogging, injection, acromegaly and neuroendocrine tumors, cost savingsMarty RRoze SKurth HDove Medical PressarticleMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2012, Iss default, Pp 39-44 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medical technology R855-855.5
spellingShingle	Medical technology R855-855.5 Marty R Roze S Kurth H Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK
description	R&eacute;mi Marty1, St&eacute;phane Roze1, Hannah Kurth21HEVA, Lyon, 2IPSEN, Boulogne-Billancourt, FranceBackground: Long-acting somatostatin receptor ligands (SRL) with product-specific formulation and means of administration are injected periodically in patients with acromegaly and neuroendocrine tumors. A simple decision-tree model aimed at comparing cost savings with ready-to-use Somatuline Autogel&reg; (lanreotide) and Sandostatin LAR&reg; (octreotide) for the UK, France, and Germany. The drivers of cost savings studied were the reduction of time to administer as well as a reduced baseline risk of clogging during product administration reported for Somatuline Autogel&reg;.Methods: The decision-tree model assumed two settings for SRL administration, ie, by either hospital-based or community-based nurses. In the case of clogging, the first dose was assumed to be lost and a second injection performed. Successful injection depended on the probability of clogging. Direct medical costs were included. A set of scenarios were run, varying the cost drivers, such as the baseline risk of clogging, SRL administration time, and percentage of patients injected during a hospital stay.Results: Costs per successful injection were less for Somatuline Autogel&reg;/Depot, ranging from Euros (EUR) 13-45, EUR 52-108, and EUR 127-151, respectively, for France, Germany, and the UK. The prices for both long-acting SRL were the same in France, and cost savings came to 100% from differences other than drug prices. For Germany and the UK, the proportion of savings due to less clogging and shorter administration time was estimated to be around 32% and 20%, respectively. Based on low and high country-specific patient cohort size estimations of individuals eligible for SRL treatment among the patient population with acromegaly and neuroendocrine tumors, annual savings were estimated to be up to EUR 2,000,000 for France, EUR 6,000,000 for Germany, and EUR 7,000,000 for the UK.Conclusion: This model suggests that increasing usage of the Somatuline device for injection of SRL might lead to substantial savings for health care providers across Europe.Keywords: clogging, injection, acromegaly and neuroendocrine tumors, cost savings
format	article
author	Marty R Roze S Kurth H
author_facet	Marty R Roze S Kurth H
author_sort	Marty R
title	Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK
title_short	Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK
title_full	Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK
title_fullStr	Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK
title_full_unstemmed	Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK
title_sort	decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in france, germany, and the uk
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/bf41481cd3594a0682ad4b04ce87116f
work_keys_str_mv	AT martyr decisiontreemodelforhealtheconomiccomparisonoftwolongactingsomatostatinreceptorliganddevicesinfrancegermanyandtheuk AT rozes decisiontreemodelforhealtheconomiccomparisonoftwolongactingsomatostatinreceptorliganddevicesinfrancegermanyandtheuk AT kurthh decisiontreemodelforhealtheconomiccomparisonoftwolongactingsomatostatinreceptorliganddevicesinfrancegermanyandtheuk
_version_	1718401457168842752

Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK

Ejemplares similares